Sight Sciences

Sight Sciences

Health Care Equipment & Supplies
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

$583M

Market Cap • 11/17/2026

2010

(16 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

11,9

P/S

6,6

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,9

EPS

—

Market Cap

Market Cap

583M

EV

546,7M

EV/Revenue

6,2

EV/EBITDA

-21,3

EV/EBIT

-20,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-409M

Profitability

Gross Margin

87,7%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

11,5%

Capex/Revenue

0%

Capex/D&A

-2,2%

Capex/OCF

0,1%

SBC/OCF

—

% PPE

2,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

15,4%

CAGR Op. Income 5Y

-10,4%

CAGR Net Income 5Y

-12,7%

CAGR EPS 5Y

-35,1%

CAGR OCF 5Y

-19,6%

Leverage

N.D./EBITDA

1,4

Debt/Equity

0%

Current Ratio

5

Quick Ratio

4,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium